Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

被引：1
|
作者：
Schwab, C. L. [1 ]
English, D. P. [1 ]
Black, J. D. [1 ]
Lopez, S. [2 ]
Bellone, S. [1 ]
Roque, D. M. [3 ]
Ratner, E. S. [1 ]
Silasi, D. A. [1 ]
Azodi, M. [1 ]
Rutherford, T. J. [1 ]
Schwartz, P. E. [1 ]
Santin, A. [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Univ Campus Biomed Rome, Rome, Italy
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 137卷
关键词：
D O I：
10.1016/j.ygyno.2015.01.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [1] Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
    Schwab, Carlton L.
    English, Diana P.
    Black, Jonathan
    Bellone, Stefania
    Lopez, Salvatore
    Cocco, Emiliano
    Bonazzoli, Elena
    Bussi, Beatrice
    Predolini, Federica
    Ferrari, Francesca
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Rutherford, Thomas
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 112 - 117
  • [2] Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
    Schwab, C. L.
    English, D. P.
    Black, J.
    Bellone, S.
    Lopez, S.
    Cocco, E.
    Bonazzoli, E.
    Bussi, B.
    Predolini, F.
    Ratner, E.
    Silasi, D.
    Azodi, M.
    Rutherford, T. J.
    Schwartz, P. E.
    Santin, A. D.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 597 - 597
  • [3] Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
    Schwab, Carlton L.
    English, Diana P.
    Roque, Dana M.
    Bellone, Stefania
    Lopez, Salvatore
    Cocco, Emiliano
    Nicoletti, Roberta
    Rutherford, Thomas J.
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (01) : 142 - 148
  • [4] Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo
    Menderes, G.
    Bonazzoli, E.
    Bellone, S.
    Black, J. D.
    Pettinella, F.
    Masserdotti, A.
    Zammataro, L.
    Lopez, S.
    Litkouhi, B.
    Ratner, E. S.
    Silasi, D. A.
    Azodi, M.
    Schwartz, P. E.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 112 - 112
  • [5] Neratinib Shows Efficacy in the Treatment of HER2/Neu Amplified Epithelial Ovarian Carcinoma In Vitro and In Vivo.
    Menderes, Gulden
    Bellone, Stefania
    Black, Jonathan D.
    Lopez, Salvatore
    Bonazzoli, Elena
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Silasi, Dan-Arin
    Litkouhi, Babak
    Ratner, Elena
    Azodi, Masoud
    Schwartz, Peter
    Santin, Alessandro D.
    REPRODUCTIVE SCIENCES, 2017, 24 : 203A - 203A
  • [6] Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
    Menderes, Gulden
    Bonazzoli, Elena
    Bellone, Stefania
    Black, Jonathan D.
    Lopez, Salvatore
    Pettinella, Francesca
    Masserdotti, Alice
    Zammataro, Luca
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    MEDICAL ONCOLOGY, 2017, 34 (05)
  • [7] Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
    Gulden Menderes
    Elena Bonazzoli
    Stefania Bellone
    Jonathan D. Black
    Salvatore Lopez
    Francesca Pettinella
    Alice Masserdotti
    Luca Zammataro
    Babak Litkouhi
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E. Schwartz
    Alessandro D. Santin
    Medical Oncology, 2017, 34
  • [8] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
    Burstein, Harold J.
    Sun, Yan
    Dirix, Luc Y.
    Jiang, Zefei
    Paridaens, Robert
    Tan, Antoinette R.
    Awada, Ahmad
    Ranade, Anantbhushan
    Jiao, Shunchang
    Schwartz, Gary
    Abbas, Richat
    Powell, Christine
    Turnbull, Kathleen
    Vermette, Jennifer
    Zacharchuk, Charles
    Badwe, Rajendra
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307
  • [9] Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents
    Solca, F.
    Baum, A.
    Himmelsbach, F.
    Amelsberg, A.
    Adolf, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 172
  • [10] Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer
    Cortes-Funes, H.
    Mendiola, C.
    Manso, L.
    Ciruelos, E.
    BREAST CANCER RESEARCH, 2009, 11 : S8 - S8
12345